VANI Company Profile and Key Details

VANI has shown mixed momentum, gaining 6.25% over the past week and -19.53% over the past quarter, though year-to-date performance is up 10.57%. Short-term trend indicators are bullishly aligned (SMA20 -3.59%, SMA50 -5.42%, SMA200 -7.02%). The stock’s 14-day RSI is 44.92 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -34.9% below its high and over 38.06% above its low. Average 10-day trading volume of 226.53 thousand shares is in line with the 3-month average of 243.42 thousand, indicating normal recent market interest.

Vivani Medical, Inc. (NASDAQ:VANI) closed at $1.18 USD, gaining $0.02 (1.72%) from the previous close of $1.16. The stock is currently mid-range between its 52-week high and low $0.92 and $1.92. With a market capitalization of about $69.71 million, Vivani Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.35). Key stats such as the average daily volume over the past year has been around 242.50 thousand shares, in line with its 52-week average. Headquartered in Alameda, CA, Vivani Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Adam Mendelsohn, the company employs approximately 37 people and listed since November 19, 2014. Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need.

Vivani Medical, Inc. generated EPS of -$0.44 over the past year. Five-year average earnings growth is 42.59%. Wall Street analysts project EPS growth of 1.58% annually over the next five years. The latest quarter delivered EPS of -$0.08. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$15.38. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $3.50. The high target offers 244.83% upside. The low target suggests 201.72% downside. The mean target is $3.75. This offers 223.28% upside. Vivani Medical, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 13, 2026, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 10.0% in March 31, 2025.

Vivani Medical, Inc. has 59.24 million shares outstanding. The public float is 30.97 million shares, elevated short interest at 0.68% of float. This equals 242.74 thousand shares. The short ratio is 1.88 days. Institutional investors hold 9.94% of the float. Insiders own 34.34%. Williams Gregg holds 34.53 million shares, Bolck Joachim Eberhard has 2.52 million shares and Mendelsohn Aaron has 188.17 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Vivani Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.04. This means the shares are trading below this model’s fair value.

Vivani Medical, Inc. (NASDAQ:VANI) shares are up 10.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vivani Medical, Inc. trading at a premium to the broader market with a P/E of -3.47. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.21, suggesting 262.93% upside. Our AI forecast model points to short-term weakness (-6.9% over two weeks), a medium-term rise (22.41% over three months), and a longer-term gain (294.83% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Vivani Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.9%, with price expected at $1.08 by June 03, 2026, within a range of $0.99 to $1.17 3-Month Outlook: Projected rise of 22.41%, reaching $1.42 by August 19, 2026, with a range of $1.38 to $1.46. 1-Year Outlook: Projected gain of 294.83%, with price at $4.58 by May 21, 2027, within a range of $0.00 to $5.64.

Vivani Medical, Inc. trades at a P/E ratio of -3.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.92 trading at moderately above to book value. The P/FCF stands at -2.57, also below market averages.